Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT02710253

Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

Led by M.D. Anderson Cancer Center · Updated on 2025-11-10

230

Participants Needed

5

Research Sites

522 weeks

Total Duration

On this page

Sponsors

M

M.D. Anderson Cancer Center

Lead Sponsor

A

Artidis

Collaborating Sponsor

AI-Summary

What this Trial Is About

This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) or has increased in size after being treated with immunotherapy. Giving radiation therapy may help to control the cancer after the disease has gotten worse after receiving immunotherapy in patients with cancer that has spread to the other places in the body.

CONDITIONS

Official Title

Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathologically confirmed diagnosis of cancer.
  • Progressive disease after prior immunotherapy or clinical need for salvage radiation as decided by physician.
  • Previous disease progression on immunotherapy or cell-based therapy.
  • At least one metastatic site suitable for radiation treatment.
  • Willing and able to provide written informed consent.
  • Age 18 years or older at consent.
  • Performance status of 0 to 2 on the ECOG scale.
  • Female participants of childbearing potential must have a negative pregnancy test within 28 days before radiation.
  • Prior radiation allowed if high dose areas do not overlap or only low dose overlaps.
  • Non-English speakers are eligible.
Not Eligible

You will not qualify if you...

  • Active scleroderma, lupus, or other rheumatologic diseases that prevent safe radiation.
  • Prior radiation within 3 months with overlapping high dose areas.
  • Not recovered from previous treatment side effects above grade 1, except certain stable or managed toxicities.
  • Active infection requiring intravenous therapy or hospitalization.
  • Psychiatric or substance abuse disorders interfering with trial participation.
  • Pregnant or planning pregnancy during the study period through 60 days after last radiation.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

MD Anderson in The Woodlands

Conroe, Texas, United States, 77384

Actively Recruiting

2

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

3

MD Anderson West Houston

Houston, Texas, United States, 77079

Actively Recruiting

4

MD Anderson League City

League City, Texas, United States, 77573

Actively Recruiting

5

MD Anderson in Sugar Land

Sugar Land, Texas, United States, 77478

Actively Recruiting

Loading map...

Research Team

J

James Welsh, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here